We are analyzing https://link.springer.com/article/10.1007/s00262-013-1491-x.

Title:
Critical role of spatial interaction between CD8+ and Foxp3+ cells in human gastric cancer: the distance matters | Cancer Immunology, Immunotherapy
Description:
In various cancer types, an abundance of FoxP3+ regulatory T cells (Treg) has been associated with an unfavorable outcome. Yet, the role of Treg on cancer immunity has been shown to be complex. In single cell marker technique, other tumor-infiltrating lymphocytes (TILs) such as cytotoxic CD8+ T cells (CTL) also influenced prognosis. This study for the first time investigates the concurrent spatial distribution pattern of CD8+ and FoxP3+ TILs and their prognostic impact in human gastric cancer. Tumor tissue microarrays of 50 patients with surgically treated adenocarcinoma of the cardia were studied. An immunohistochemical double staining of CD8+ and FoxP3+ TILs was performed. Cell counts and cell-to-cell distances in tumor epithelium and stroma were evaluated with image-processing software. Metastasis-free survival, no-evidence-of-disease survival, and overall survival were investigated (mean follow-up time 6.9 years). High intraepithelial infiltration of CD8+ and FoxP3+ TIL was associated with the improved 10-year metastasis-free survival (83 vs. 54 %, p = 0.04 and 85 vs. 59 %, p = 0.09, respectively). Considering cell-to-cell distance and comparing patients with functional (30–110 μm) versus nonfunctional distances of CD8+ and FoxP3+ TILs, 10-year survival rates differed between 89 and 55 % (p = 0.009), respectively. Prognostic influence of tumor-infiltrating immune cells in gastric cancer critically depends on their cell-to-cell distance. FoxP3+ TILs must be located within a distance between 30 and 110 μm of CD8+ T cells to positively impact on prognosis.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com might be plotting its profit, but the way they're doing it isn't detectable yet.

Keywords {🔍}

cancer, article, pubmed, google, scholar, gastric, cells, cas, foxp, regulatory, tumorinfiltrating, prognosis, central, lymphocytes, survival, immunol, human, haas, distel, tils, prognostic, patients, access, privacy, cookies, content, role, distance, cell, dois, information, publish, search, immunology, feichtenbeiner, grabenbauer, treg, tumor, cardia, infiltration, carcinoma, clin, wang, oncol, fujii, immunother, data, log, journal, research,

Topics {✒️}

naturally occurring cd4+ cd25+ regulatory long-term disease-free survival foxp3-positive tumor-infiltrating lymphocytes cd8-alpha t-cell infiltration month download article/chapter tumor-infiltrating immune cells cd4+ cd25high regulatory t-cells advanced gastric carcinoma intra-tumoral infiltrating macrophages potent anti-tumor killer tumor-draining lymph nodes article cancer immunology increased tumor-infiltrating cd8 stromal regulatory t-cells sentinel lymph-node metastasis related subjects intratumoural foxp3-positive regulatory tumour-infiltrating lymphocytes tumor-infiltrating lymphocytes full article pdf tumor-infiltrating foxp3+ metastasis-free survival privacy choices/manage cookies sentinel lymph node ten-year survival intratumoral foxp3+rorγt+ gastric cancer progression human gastric cancer article feichtenbeiner gastric cancer prevention resectable gastric cancer improved patient prognosis european economic area immunohistochemical double staining cox-2-dependent manner postoperative adjuvant chemotherapy common public hospital cancerous hla class excellent technical assistance independent prognostic factor conditions privacy policy check access instant access colorectal cancer differs surgically treated adenocarcinoma versus nonfunctional distances cancers cd8-positive electronic supplementary material article log accepting optional cookies

Questions {❓}

Haas M, Buttner M, Rau TT, Fietkau R, Grabenbauer GG, Distel LV (2011) Inflammation in gastric adenocarcinoma of the cardia: how do EBV infection, Her2 amplification and cancer progression influence tumor-infiltrating lymphocytes?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Critical role of spatial interaction between CD8+ and Foxp3+ cells in human gastric cancer: the distance matters
         description:In various cancer types, an abundance of FoxP3+ regulatory T cells (Treg) has been associated with an unfavorable outcome. Yet, the role of Treg on cancer immunity has been shown to be complex. In single cell marker technique, other tumor-infiltrating lymphocytes (TILs) such as cytotoxic CD8+ T cells (CTL) also influenced prognosis. This study for the first time investigates the concurrent spatial distribution pattern of CD8+ and FoxP3+ TILs and their prognostic impact in human gastric cancer. Tumor tissue microarrays of 50 patients with surgically treated adenocarcinoma of the cardia were studied. An immunohistochemical double staining of CD8+ and FoxP3+ TILs was performed. Cell counts and cell-to-cell distances in tumor epithelium and stroma were evaluated with image-processing software. Metastasis-free survival, no-evidence-of-disease survival, and overall survival were investigated (mean follow-up time 6.9 years). High intraepithelial infiltration of CD8+ and FoxP3+ TIL was associated with the improved 10-year metastasis-free survival (83 vs. 54 %, p = 0.04 and 85 vs. 59 %, p = 0.09, respectively). Considering cell-to-cell distance and comparing patients with functional (30–110 μm) versus nonfunctional distances of CD8+ and FoxP3+ TILs, 10-year survival rates differed between 89 and 55 % (p = 0.009), respectively. Prognostic influence of tumor-infiltrating immune cells in gastric cancer critically depends on their cell-to-cell distance. FoxP3+ TILs must be located within a distance between 30 and 110 μm of CD8+ T cells to positively impact on prognosis.
         datePublished:2013-10-30T00:00:00Z
         dateModified:2013-10-30T00:00:00Z
         pageStart:111
         pageEnd:119
         sameAs:https://doi.org/10.1007/s00262-013-1491-x
         keywords:
            Regulatory T cells
            Cytotoxic T cells
            Tumor-infiltrating lymphocytes
            Gastric cancer
            Cancer immunology
            Immune evasion
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-013-1491-x/MediaObjects/262_2013_1491_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-013-1491-x/MediaObjects/262_2013_1491_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-013-1491-x/MediaObjects/262_2013_1491_Fig3_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:63
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Berlin Heidelberg
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Anita Feichtenbeiner
               affiliation:
                     name:Friedrich-Alexander-University of Erlangen-Nürnberg
                     address:
                        name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Matthias Haas
               affiliation:
                     name:Charité Universitätsmedizin
                     address:
                        name:Department of Radiology, Charité Universitätsmedizin, Berlin, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Maike Büttner
               affiliation:
                     name:Friedrich-Alexander-University of Erlangen-Nürnberg
                     address:
                        name:Institute of Pathology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gerhard G. Grabenbauer
               affiliation:
                     name:Friedrich-Alexander-University of Erlangen-Nürnberg
                     address:
                        name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rainer Fietkau
               affiliation:
                     name:Friedrich-Alexander-University of Erlangen-Nürnberg
                     address:
                        name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Luitpold V. Distel
               affiliation:
                     name:Friedrich-Alexander-University of Erlangen-Nürnberg
                     address:
                        name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Critical role of spatial interaction between CD8+ and Foxp3+ cells in human gastric cancer: the distance matters
      description:In various cancer types, an abundance of FoxP3+ regulatory T cells (Treg) has been associated with an unfavorable outcome. Yet, the role of Treg on cancer immunity has been shown to be complex. In single cell marker technique, other tumor-infiltrating lymphocytes (TILs) such as cytotoxic CD8+ T cells (CTL) also influenced prognosis. This study for the first time investigates the concurrent spatial distribution pattern of CD8+ and FoxP3+ TILs and their prognostic impact in human gastric cancer. Tumor tissue microarrays of 50 patients with surgically treated adenocarcinoma of the cardia were studied. An immunohistochemical double staining of CD8+ and FoxP3+ TILs was performed. Cell counts and cell-to-cell distances in tumor epithelium and stroma were evaluated with image-processing software. Metastasis-free survival, no-evidence-of-disease survival, and overall survival were investigated (mean follow-up time 6.9 years). High intraepithelial infiltration of CD8+ and FoxP3+ TIL was associated with the improved 10-year metastasis-free survival (83 vs. 54 %, p = 0.04 and 85 vs. 59 %, p = 0.09, respectively). Considering cell-to-cell distance and comparing patients with functional (30–110 μm) versus nonfunctional distances of CD8+ and FoxP3+ TILs, 10-year survival rates differed between 89 and 55 % (p = 0.009), respectively. Prognostic influence of tumor-infiltrating immune cells in gastric cancer critically depends on their cell-to-cell distance. FoxP3+ TILs must be located within a distance between 30 and 110 μm of CD8+ T cells to positively impact on prognosis.
      datePublished:2013-10-30T00:00:00Z
      dateModified:2013-10-30T00:00:00Z
      pageStart:111
      pageEnd:119
      sameAs:https://doi.org/10.1007/s00262-013-1491-x
      keywords:
         Regulatory T cells
         Cytotoxic T cells
         Tumor-infiltrating lymphocytes
         Gastric cancer
         Cancer immunology
         Immune evasion
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-013-1491-x/MediaObjects/262_2013_1491_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-013-1491-x/MediaObjects/262_2013_1491_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-013-1491-x/MediaObjects/262_2013_1491_Fig3_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:63
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Berlin Heidelberg
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Anita Feichtenbeiner
            affiliation:
                  name:Friedrich-Alexander-University of Erlangen-Nürnberg
                  address:
                     name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Matthias Haas
            affiliation:
                  name:Charité Universitätsmedizin
                  address:
                     name:Department of Radiology, Charité Universitätsmedizin, Berlin, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Maike Büttner
            affiliation:
                  name:Friedrich-Alexander-University of Erlangen-Nürnberg
                  address:
                     name:Institute of Pathology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gerhard G. Grabenbauer
            affiliation:
                  name:Friedrich-Alexander-University of Erlangen-Nürnberg
                  address:
                     name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rainer Fietkau
            affiliation:
                  name:Friedrich-Alexander-University of Erlangen-Nürnberg
                  address:
                     name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Luitpold V. Distel
            affiliation:
                  name:Friedrich-Alexander-University of Erlangen-Nürnberg
                  address:
                     name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:63
Organization:
      name:Springer Berlin Heidelberg
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Friedrich-Alexander-University of Erlangen-Nürnberg
      address:
         name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
         type:PostalAddress
      name:Charité Universitätsmedizin
      address:
         name:Department of Radiology, Charité Universitätsmedizin, Berlin, Germany
         type:PostalAddress
      name:Friedrich-Alexander-University of Erlangen-Nürnberg
      address:
         name:Institute of Pathology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
         type:PostalAddress
      name:Friedrich-Alexander-University of Erlangen-Nürnberg
      address:
         name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
         type:PostalAddress
      name:Friedrich-Alexander-University of Erlangen-Nürnberg
      address:
         name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
         type:PostalAddress
      name:Friedrich-Alexander-University of Erlangen-Nürnberg
      address:
         name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Anita Feichtenbeiner
      affiliation:
            name:Friedrich-Alexander-University of Erlangen-Nürnberg
            address:
               name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
               type:PostalAddress
            type:Organization
      name:Matthias Haas
      affiliation:
            name:Charité Universitätsmedizin
            address:
               name:Department of Radiology, Charité Universitätsmedizin, Berlin, Germany
               type:PostalAddress
            type:Organization
      name:Maike Büttner
      affiliation:
            name:Friedrich-Alexander-University of Erlangen-Nürnberg
            address:
               name:Institute of Pathology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
               type:PostalAddress
            type:Organization
      name:Gerhard G. Grabenbauer
      affiliation:
            name:Friedrich-Alexander-University of Erlangen-Nürnberg
            address:
               name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
               type:PostalAddress
            type:Organization
      name:Rainer Fietkau
      affiliation:
            name:Friedrich-Alexander-University of Erlangen-Nürnberg
            address:
               name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
               type:PostalAddress
            type:Organization
      name:Luitpold V. Distel
      affiliation:
            name:Friedrich-Alexander-University of Erlangen-Nürnberg
            address:
               name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
      name:Department of Radiology, Charité Universitätsmedizin, Berlin, Germany
      name:Institute of Pathology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
      name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
      name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
      name:Department of Radiation Oncology of the University Hospitals, Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(128)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.61s.

LINK . SPRINGER . COM {}